Table 2 Technical characteristics of plasma exchange therapy 1
From: Efficacy and safety of plasma exchange for Kawasaki disease with coronary artery dilatation
Patient | Vascular access | Start of PE (day) | Duration for PE (days) | Total operation time of PE (h) |
|---|---|---|---|---|
1 | A-V | 27 | 3 | 19.5 |
2 | 7-Fr catheter (FV) | 12 | 3 | 13.0 |
3 | 6-Fr catheter (FV) | 9 | 4 | 15.0 |
4 | 8-Fr catheter (FV) | 13 | 3 | 5.0 |
5 | 6-Fr catheter (FV) | 11 | 3 | 8.0 |
6 | 6-Fr catheter (FV) | 10 | 4 | 11.5 |
7 | 6-Fr catheter (FV) | 12 | 3 | 8.0 |
8 | 6-Fr catheter (FV) | 11 | 4 | 10.0 |
9 | 6-Fr catheter (FV) | 21 | 1 | 4.5 |
10 | 8-Fr catheter (FV) | 10 | 3 | 7.5 |